Literature DB >> 15172119

Effect of LY293111 in combination with gemcitabine in colonic cancer.

Rene Hennig1, Xian-Zhong Ding, Wei-Gang Tong, Richard C Witt, Borko D Jovanovic, Thomas E Adrian.   

Abstract

New adjuvant therapies are needed for the treatment of stage III colon cancer. The essential fatty acids, linoleic and arachidonic acid enhance tumorigenesis through the cyclooxygenase and lipoxygenase pathways. Leukotriene B4 (LTB4) is a product of 5-lipoxygenase (5-LOX) which has tumor-promoting effects. The LTB4 receptor antagonist, LY293111 inhibited tumor growth and induced apoptosis in vitro. The effectiveness of LY293111, alone and in combination with gemcitabine was investigated in a heterotopic xenograft model in athymic mice using HT29 and LoVo human colonic cancer cells. The combined therapy markedly inhibited tumor growth and could warrant consideration as a new therapeutic option. Copyright 2004 Elsevier Ireland Ltd.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15172119     DOI： 10.1016/j.canlet.2004.02.023

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  9 in total

Review 1.  Regulation of inflammation in cancer by eicosanoids.

Authors:  Emily R Greene; Sui Huang; Charles N Serhan; Dipak Panigrahy
Journal:  Prostaglandins Other Lipid Mediat       Date:  2011-08-16       Impact factor: 3.072

2.  Up-regulation of BLT2 is critical for the survival of bladder cancer cells.

Authors:  Ji Min Seo; Kyung Jin Cho; Eun Young Kim; Man Ho Choi; Bong Chul Chung; Jae Hong Kim
Journal:  Exp Mol Med       Date:  2011-03-31       Impact factor: 8.718

Review 3.  Eicosanoids and cancer.

Authors:  Dingzhi Wang; Raymond N Dubois
Journal:  Nat Rev Cancer       Date:  2010-02-19       Impact factor: 60.716

4.  Leukotrienes promote stem cell self-renewal and chemoresistance in acute myeloid leukemia.

Authors:  Alec W Stranahan; Iryna Berezniuk; Sohini Chakraborty; Faye Feller; Mona Khalaj; Christopher Y Park
Journal:  Leukemia       Date:  2022-04-23       Impact factor: 12.883

Review 5.  Cysteinyl leukotrienes and their receptors: bridging inflammation and colorectal cancer.

Authors:  Sayeh Savari; Katyayni Vinnakota; Yuan Zhang; Anita Sjölander
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

6.  A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours.

Authors:  Tara Baetz; Elizabeth Eisenhauer; Lillian Siu; Martha MacLean; Karen Doppler; Wendy Walsh; Bryn Fisher; Azhar Z Khan; Dinesh P de Alwis; A Weitzman; Leslie H Brail; Malcolm Moore
Journal:  Invest New Drugs       Date:  2006-12-05       Impact factor: 3.651

7.  The Role of PPARgamma Receptors and Leukotriene B(4) Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer.

Authors:  Thomas E Adrian; Rene Hennig; Helmut Friess; Xianzhong Ding
Journal:  PPAR Res       Date:  2009-01-27       Impact factor: 4.964

8.  Combination Therapy of PPARgamma Ligands and Inhibitors of Arachidonic Acid in Lung Cancer.

Authors:  Jordi Tauler; James L Mulshine
Journal:  PPAR Res       Date:  2009-03-04       Impact factor: 4.964

9.  Frondanol, a Nutraceutical Extract from Cucumaria frondosa, Attenuates Colonic Inflammation in a DSS-Induced Colitis Model in Mice.

Authors:  Sandeep B Subramanya; Sanjana Chandran; Saeeda Almarzooqi; Vishnu Raj; Aisha Salem Al Zahmi; Radeya Ahmed Al Katheeri; Samira Ali Al Zadjali; Peter D Collin; Thomas E Adrian
Journal:  Mar Drugs       Date:  2018-04-30       Impact factor: 5.118
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.